AAAAAA
Results:
1-8
|
Results: 8
Authors:
Jimenez, B
Volpert, OV
Reiher, F
Chang, LF
Munoz, A
Karin, M
Bouck, N
Citation: B. Jimenez et al., c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1, ONCOGENE, 20(26), 2001, pp. 3443-3448
Authors:
Filleur, S
Volpert, OV
Degeorges, A
Voland, C
Reiher, F
Clezardin, P
Bouck, N
Cabon, F
Citation: S. Filleur et al., In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects, GENE DEV, 15(11), 2001, pp. 1373-1382
Authors:
Stellmach, V
Crawford, SE
Zhou, W
Bouck, N
Citation: V. Stellmach et al., Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor, P NAS US, 98(5), 2001, pp. 2593-2597
Authors:
Lawler, J
Miao, WM
Duquette, M
Bouck, N
Bronson, RT
Hynes, RO
Citation: J. Lawler et al., Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice, AM J PATH, 159(5), 2001, pp. 1949-1956
Authors:
Zhang, M
Volpert, O
Shi, YH
Bouck, N
Citation: M. Zhang et al., Maspin is an angiogenesis inhibitor, NAT MED, 6(2), 2000, pp. 196-199
Authors:
Jimenez, B
Volpert, OV
Crawford, SE
Febbraio, M
Silverstein, RL
Bouck, N
Citation: B. Jimenez et al., Signals leading to apoptosis-dependent inhibition of neovascularization bythrombospondin-1, NAT MED, 6(1), 2000, pp. 41-48
Authors:
Gradishar, WJ
Soff, G
Liu, JG
Cisneros, A
French, S
Rademaker, A
Benson, AB
Bouck, N
Citation: Wj. Gradishar et al., A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients, ONCOL-BASEL, 58(4), 2000, pp. 324-333
Authors:
Lucas, R
Holmgren, L
Garcia, I
Jimenez, B
Mandriota, SJ
Borlat, F
Sim, BKL
Wu, Z
Grau, GE
Shing, Y
Soff, GA
Bouck, N
Pepper, MS
Citation: R. Lucas et al., Multiple forms of angiostatin induce apoptosis in endothelial cells, BLOOD, 92(12), 1998, pp. 4730-4741
Risultati:
1-8
|